Treatment News : New Guidelines Get NYC Youths With HIV on ARVs Earlier

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » February 2014

Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


February 4, 2014

New Guidelines Get NYC Youths With HIV on ARVs Earlier

Following a 2009 shift in HIV treatment guidelines that recommended beginning antiretrovirals (ARVs) at higher CD4 counts, young New Yorkers with HIV began treatment earlier in the course of their infection, aidsmap reports. Eighteen percent of them had acquired a drug-resistant strain of the virus.

Publishing their findings in Clinical Infectious Diseases, researchers conducted a multicenter, retrospective cohort study of the New Yorkers ages 13 to 25 who were diagnosed with HIV within one year of their entry into care at one of the clinics included in the study and who entered care between January 2007 and June 2011.

The researchers identified 685 potential subjects and narrowed them down to 331 who met all the criteria for the study. The cohort’s average CD4 count upon entering care was 452. A total of 191 of the young people (58 percent) began ARV treatment. Before the 2009 guideline shift, the average CD4 count upon starting ARVs was 261; after the shift, the average CD4 count was 364.

Out of the 212 study participants who had undergone resistance testing before beginning HIV treatment, 38 (18 percent) had a major drug-resistance mutation. The latter period of the study saw a greater likelihood of drug resistance among the participants.

To read the aidsmap story, click here.

To read the study abstract, click here.

Search: HIV, treatment guidelines, aidsmap, antiretroviral initiation, drug resistance, Clinical Infectious Diseases, CD4 count.

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.